Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Olema Oncology公佈了1b/2期Palazestrant研究的中期結果，稱迄今爲止在所有符合CBR條件的患者中觀察到的臨床獲益率爲85％
Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Olema Oncology公佈了1b/2期Palazestrant研究的中期結果，稱迄今爲止在所有符合CBR條件的患者中觀察到的臨床獲益率爲85％
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。